Pharmaceutical Raw Materials
Veterinary API
Antiallergic Drugs
Hormones and Endocrine Drugs
Drug Metabolism
Pharmaceutical Intermediates
Synthetic Anti Infective Drugs
Specialty Drugs
Vitamins and Minerals Medicines
Feed Drug Additive
Antineoplastic Agents
Nervous System Drugs
Respiratory Drugs
Diagnostic Agents
Anti Stress Drugs
Antipyretic Analgesics
Antiparasitic Drugs
Circulatory System Drugs
Biochemicals
Blood System Drugs
Immune System Medication
Pharmaceutical Excipients
Fluid, Electrolyte, and Acid-Base Balance
Urinary System Drugs
Antibiotics
Anesthetic Agents
Inhibitors
Other Chemical Drugs
Digestive System Drugs
CAS:915087-33-1
Molecular Formula:C21H16F4N4O2S
Alias
More Information
Mdv 3100; Xtandi; Unii-93T0T9Gknu; [14C]-Enzalutamide; N-Methyl-4-[3-(4-Cyano-3-Trifluoromethylphenyl)-5,5-Dimethyl-4-Oxo-2-Thioxoimidazolidin-1-Yl]-2-Fluorobenzamide; 4-(3-(4-Cyano-3-(Trifluoromethyl)Phenyl)-5,5-Dimethyl-4-Oxo-2-Thioxoimidazolidin-1-Yl)-2-Fluoro-N-Methylbenzamide
Brief Introduction
Enzalutamide is an oral androgen receptor antagonist. At present, it has been approved by clinical research and FDA (food and Drug Administration) for the treatment of metastatic castration tolerant prostate cancer after chemotherapy (i.e. such patients with prostate cancer whose tumor or cancer cells are still growing after chemotherapy), which can prolong the survival time of patients.
CAS:923564-51-6
Molecular Formula:C47H55ClF3N5O6S3
Alias
More Information
Navitoclax; ABT 263; ABT263; (R)-4-(4-((4'-Chloro-4,4-Dimethyl-3,4,5,6-Tetrahydro-[1,1'-Biphenyl]-2-yl)Methyl)Piperazin-1-yl)-N-((4-((4-Morpholino-1-(Phenylthio)Butan-2-yl)Amino)-3-((Trifluoromethyl)Sulfonyl)Phenyl)Sulfonyl)Benzamide; 4-[4-[[2-(4-Chlorophenyl)-5,5-Dimethyl-1-Cyclohexen-1-yl]Methyl]-1-Piperazinyl]-N-[[4-[[(1R)-3-(4-Morpholinyl)-1-[(Phenylthio)Methyl]Propyl]Amino]-3-[(Trifluoromethyl)Sulfonyl]Phenyl]Sulfonyl]Benzamide; 4-[4-[[2-(4-Chlorophenyl)-5,5-Dimethylcyclohexen-1-yl]Methyl]Piperazin-1-yl]-N-[4-[[(2R)-4-Morpholin-4-yl-1-Phenylsulfanylbutan-2-yl]Amino]-3-(Trifluoromethylsulfonyl)Phenyl]Sulfonylbenzamide; (R)-4-(4-((2-(4-Chlorophenyl)-5,5-Dimethylcyclohex-1-enyl)Methyl)Piperazin-1-yl)-N-(4-(4-Morpholino-1-(Phenylthio)Butan-2-Ylamino)-3-(Trifluoromethylsulfonyl)p; (R)-4-(4-((2-(4-Chlorophenyl)-5,5-Dimethylcyclohex-1-enyl)Methyl)Piperazin-1-yl)-N-(4-(4-Morpholino-1-(Phenylthio)Butan-2-Ylamino)-3-(Trifluoromethylsulfonyl)Phenylsulfonyl)Benzamide; 4-(4-{[2-(4-Chlorophenyl)-5,5-Dimethylcyclohex-1-en-1-yl]Methyl}Piperazin-1-yl)-N-({4-({(1R)-3-Morpholin-4-yl-1-[(Phenylsulfanyl)Methyl]Propyl}Amino)-3-[(Trifluoromethyl)Sulfonyl]Phenyl}Sulfonyl)Benzamide; 4-(4-{[2-(4-Chlorophenyl)-5,5-Dimethylcyclohex-1-En-1-Yl]Methyl}Piperazin-1-Yl)-N-[(4-{[(2r)-4-(Morpholin-4-Yl)-1-(Phenylsulfanyl)Butan-2-Yl]Amino}-3-[(Trifluoromethyl)Sulfonyl]Phenyl)Sulfonyl]Benzamide; Navitoclaxum; C47H55ClF3N5O6S3; 4-(4-((2-(4-Chlorophenyl)-5,5-Dimethylcyclohex-1-EN-1-YL)Methyl)Piperazin-1-YL)-N-((4-(((2R)-4-(Morpholin-4-YL)-1-(Phenylsulfanyl)Butan-2-YL)Amino)-3-((Trifluoromethyl)Sulfonyl)Phenyl)Sulfonyl)Benzamide; ABT-263,Navitoclax; ABT-263 In Bulk; Navitoclax, ABT-263; ABT-263 - Navitoclax; 4-[4-[[2-(4-Chlorophenyl)-5,5-Dimethyl-1-Cyclohexen-1-yl]Methyl]-1-Piperazinyl]-N-[[4-[[(1R)-3-(4-mo; 4-[4-[[2-(4-Chlorophenyl)-5,5-Dimethyl-Cyclohexen-1-yl]Methyl]Piperazin-1-yl]-N-[4-[[(1R)-3-Morpholino-1-(Phenylsulfanylmethyl)Propyl]Amino]-3-(Trifluoromethylsulfonyl)Phenyl]Sulfonyl-Benzamide; 4-[4-[[2-(4-Chlorophenyl)-5,5-Dimet; (R)-4-(4-((4-Chloro-4,4-Dimethyl-3,4,5,6-Tetrahydro-[1,1-Biphenyl]-2-yl)Methyl)Piperazin-1-yl)-N-((4-((4-Morpholino-1-(Phenylthio)Butan-2-yl)Amino)-3-((Trifluoromethyl)Sulfonyl)Phenyl)Sulfonyl)Benzamide; 4-(4-((2-(4-Chlorophenyl)-5,5-Dimethylcyclohex-1-EN-1-YL)Methyl)Piperazin-1-YL)-N-(4-(((2R)-4-(Morpholin-4-YL)-1-(Phenylsulfanyl)Butan-2-YL)Amino)-3-(Trifluoromethanesulfonyl)Benzenesulfonyl)Benzamide; 4-(4-{[2-(4-Chlorophenyl)-5,5-Dimethylcyclohex-1-en-1-yl]Methyl}Piperazin-1-yl)-N-({4-({(1R)-3-(Morpholin-4-yl)-1-[(Phenylsulfanyl)Methyl]Propyl}Amino)-3-[(Trifluoromethyl)Sulfonyl]Phenyl}Sulfonyl)Benzamide; 4-[4-[[2-(4-Chlorophenyl)-5,5-Dimethyl-1-Cyclohexen-1-yl]Methyl]-1-Piperazinyl]-N-[[4-[[(1R)-3-(4-Morpholinyl)-1-[(Phenylthio)Methyl]Propyl]Amino]-3-[(Trifluoromethyl)Sulfonyl]Phenyl]Sulfonyl]Benzamide;ABT 263;Benzamide, 4-(4-((2-(4-Chlorophenyl)-5,5-dime; 4-{4-[(4'-Chloro-4,4-Dimethyl-3,4,5,6-Tetrahydro[Biphenyl]-2-yl)Methyl]Piperazin-1-yl}-N-[(4-{[(2R)-4-(Morpholin-4-yl)-1-(Phenylsulfanyl)Butan-2-yl]Amino}-3-[(Trifluoromethyl)Sulfonyl]Phenyl)Sulfonyl]Benzamide; Benzamide, 4-(4-((2-(4-Chlorophenyl)-5,5-Dimethyl-1-Cyclohexen-1-YL)Methyl)-1- Piperazinyl)-N-((4-(((1R)-3-(4-Morpholinyl)-1-((Phenylthio)Methyl)Propyl)Amino)-3-((Trifluoromethyl)Sulfonyl)Phenyl)Sulfonyl)-; Benzamide, 4-(4-((2-(4-Chlorophenyl)-5,5-Dimethyl-1-Cyclohexen-1-yl)Methyl)-1-Piperazinyl)-N-((4-(((1R)-3-(4-Morpholinyl)-1-((Phenylthio)Methyl)Propyl)Amino)-3-((Trifluoromethyl)Sulfonyl)Phenyl)Sulfonyl)-; N-(4-{4-[2-(4-Chlorophenyl)-5,5-Dimethyl-Cyclohex-1-Enylmethyl]-Piperazin-1-yl}-Benzoyl)-4-((r)-3-Morpholin-4-yl-1-Phenylsulfanylmethyl-Propylamino)-3-Trifluoromethanesulfonyl-Benzenesulfonamide
Brief Introduction
ABT 263 is a new inhibitor of the anti-apoptotic BCL-2 protein; a promising new drug against cancer. It is a potent Bcl-2 family inhibitor.
CAS:17374-26-4
Molecular Formula:C6HBr4N3
Alias
More Information
4,5,6,7-Tetrabromobenzotriazole; 4,5,6,7-Tetrabromo-2H-Benzotriazole; 4,5,6,7-Tetrabromo-2-Azabenzimidazole 4,5,6,7-Tetrabromobenzotriazole; 4,5,6,7-Tetrabromo-2-Azabenzimidazole,4,5,6,7-Tetrabromobenzotriazole; TBB
Brief Introduction
TBB is one of the most selective protein kinase inhibitors known, and when tested against a panel of 33 serine/threonine and tyrosine protein kinases, only three exhibited moderate inhibition by TBB, with Ki values one to two orders of magnitude higher than that for CK2.
CAS:2244035-16-1
Molecular Formula:C26H24ClNO3
Alias
More Information
CS-0089777; (E)-3-[6-[1-(2-Chloro-6-Cyclopropylphenyl)Ethoxy]-4-Cyclopropylquinolin-3-yl]prop-2-Enoic acid; 2-Propenoic acid, 3-[6-[1-(2-Chloro-6-Cyclopropylphenyl)Ethoxy]-4-Cyclopropyl-3-Quinolinyl]-; HY-125176
Brief Introduction
G907 is a selective small-molecule antagonist of ATP-binding cassette (ABC) transporter, MsbA. It inhibits purified E. coli MsbA in amphipols with an IC50 of 18 nM. G907 traps MsbA in an inward-facing
CAS:1207753-03-4
Molecular Formula:C44H67N5O4
Alias
More Information
MK 3118; MK-3118; SCY 078; (1S,4aR,6aS,7R,8R,10aR,10bR,12aR,14R,15R)-15-[[(2R)-2-Amino-2,3,3-Trimethylbutyl]oxy]-8-[(1R)-1,2-Dimethylpropyl]-14-[5-(4-Pyridinyl)-1H-1,2,4-Triazol-1-yl]-1,6,6a,7,8,9,10,10a,10b,11,12,12a-Dodecahydro-1,6a,8,10a-Tetramethyl-4H-1,4a-Propano-2H-Phenanthro[1,2-c]Pyran-7-Carboxylic acid; Ibrexafungerp; Ibrexafungerp(SCY-078)
Brief Introduction
Antifungal (SCY-078), a novel oral and intravenous (IV) drug for the treatment of severe and life-threatening invasive fungal infections in humans.
Inquiry (
10
/ 10
)
Clear All
Sign In
Error!